Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma(540 views) Pedicini P, Nappi A, Strigari L, Jereczek-Fossa BA, Alterio D, Cremonesi M, Botta F, Vischioni B, Caivano R, Fiorentino A, Improta G, Storto G, Benassi M, Orecchia R, Salvatore M
Keywords: Cell Loss Factor, Doubling Time, Egfr, Potential Doubling Time, Epidermal Growth Factor Receptor, Article, Cancer Radiotherapy, Cell Proliferation, Female, Flow Cytometry, Head And Neck Carcinoma, Human, Human Tissue, Immunohistochemistry, Major Clinical Study, Mouth Cavity, Pharynx, Protein Expression, Radiation Dose, Squamous Cell Carcinoma, Tumor Growth, Acceleration, Disease Progression, Head And Neck Neoplasms, Prognosis, Radiotherapy Dosage, Treatment Outcome, Tumor Markers, Biological,
Affiliations: *** IBB - CNR ***
I.R.C.C.S. C.R.O.B. Regional Cancer Hospital, Rionero in Vulture, Italy. ppiern@libero.it
Regina Elena National Cancer Institute, Roma, Italy
I.E.O. European Institute of Oncology, Milan, Italy
University of Milan, Milan, Italy
Scientific Institute of Tumours of Romagna I.R.S.T, Meldola, Italy
I.R.C.C.S SDN Foundation, Naples, Italy
Division of Radiation Oncology and Radiobiology, National Center for Oncological Hadrontherapy CNAO, Pavia, Italy
I. R. C. C. S. C. R. O. B. Regional Cancer Hospital, Rionero in Vulture, Italy. ppiern@libero. it
I. E. O. European Institute of Oncology, Milan, Italy
I. R. C. C. S SDN Foundation, Naples, Italy
References: Not available.
Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma
PURPOSE: To investigate the correlation between the expression of Epidermal Growth Factor receptor (EGFr) and the reduction of the effective doubling time (TD) during radiotherapy treatment and also to determine the dose per fraction to be taken into account when the overall treatment time (OTT) is reduced in accelerated radiotherapy of head and neck squamous cell carcinoma (HNSCC).; METHODS: A survey of the published papers comparing 3-years of local regional control rate (LCR) for a total of 2162 patients treated with conventional and accelerated radiotherapy and with a pretreatment assessment of EGFr expression, was made. Different values of TD were obtained by a model incorporating the overall time corrected biologically effective dose (BED) and a 3-year clinical LCR for high and low EGFr groups of patients (HEGFr and LEGFr), respectively. By obtaining the TD from the above analysis and the sub-sites' potential doubling time (Tpot) from flow cytometry and immunohistochemical methods, we were able to estimate the average TD for each sub-site included in the analysis. Moreover, the dose that would be required to offset the modified proliferation occurring in one day (Dprolif), was estimated.; RESULTS: The averages of TD were 77 (27-90)95% days in LEGFr and 8.8 (7.3-11.0)95% days in HEGFr, if an onset of accelerated proliferation TK at day 21 was assumed. The correspondent HEGFr sub-sites' TD were 5.9 (6.6), 5.9 (6.6), 4.6 (6.1), 14.3 (12.9) days, with respect to literature immunohistochemical (flow cytometry) data of Tpot for Oral-Cavity, Oro-pharynx, Hypo-pharynx, and Larynx respectively. The Dprolif for the HEGFr groups were 0.33 (0.29), 0.33 (0.29), 0.42 (0.31), 0.14 (0.15) Gy/day if alpha=0.3 Gy-1 and alpha/beta=10 Gy were assumed.; CONCLUSIONS: A higher expression of the EGFr leads to enhanced proliferation. This study allowed to quantify the extent of the effect which EGFr expression has in terms of reduced TD and Dprolif for each head and neck sub-site.
Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma
No results.
Correlation between EGFr expression and accelerated proliferation during radiotherapy of head and neck squamous cell carcinoma